Physician profile
David Kanani
NPI 1982931838
$602.12
in general payments reported to CMS, 2019-2025
12 companies · $311 in 2025
The $311 reported for 2025 was more than what 84% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $220 · 2024: $70.78 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $127.72 | 2023-2025 | |
| Lilly USA, LLC | $80.40 | 2023-2024 | Zepbound |
| Cleerly, INC. | $65.45 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Exact Sciences Corporation | $52.47 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $44.63 | 2024-2025 | Breztri, Airsupra |
| Stryker Corporation | $43.70 | 2023 | Insignia |
| Heartflow, INC. | $41.80 | 2025 | |
| Amgen INC. | $40.84 | 2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $30.94 | 2023 | |
| Abbvie INC. | $26.34 | 2025 | |
| Novo Nordisk INC | $25.57 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.26 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kanani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.